Global Skin Cancer

Skin Cancer Comprehensive Study by Type (Basal Cell Carcinoma, Squamous Cell Carcinoma, Malignant Melanoma), Application (Hospital, Clinics, Diagnostic Centers, Cancer Research Institute), Chemotherapy Type (Systemic, Targeted), Non- Invasive Treatment Type (Radiotherapy, Photodynamic Therapy, Cryotherapy, Laser Therapy), Treatment Type (Surgery, Medication) Players and Region - Global Market Outlook to 2030

Skin Cancer Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 7.2%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Skin Cancer
Skin cancer is the abnormal growth of skin cells that most commonly develop on skin that is exposed to the sun. However, this common form of cancer can also appear in areas of your skin that are not normally exposed to sunlight. The skin is the largest organ in the body that helps regulate body temperature, protects against harmful radiation, and excrete toxic substances through sweat and sensation. Skin cancer is the most common type of cancer caused by the abnormal growth of skin cells. It is estimated that 90% of skin cancers are caused primarily by solar and artificial ultraviolet (UV) radiation. The World Health Organization predicts that approximately 2-3 million cases of non-melanoma skin cancer and 1-1.5 million cases of melanoma skin cancer are reported each year, with one in three cancer diagnosed being skin cancer and one in five Americans occurring during their lifetime Sufferers of skin cancer. It has also been estimated that a 10% decrease in the ozone layer leads to an additional 0.3 million non-melanoma cases and around 4,500 melanoma cases. There are three main types of skin cancer, namely basal cell carcinoma, squamous cell carcinoma, and melanoma. Squamous cells that make up the top layer of the epidermis, basal cells, i.e. H. Round cells below the squamous cells, and melanocytes that produce melanin are present in the lower part of the epidermis. Skin cancer forms in basal cells or squamous cell carcinoma. Treatment for skin cancer can vary based on the general health of the patient, type of cancer, stage of cancer, part of the body affected, tumor size, etc.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR7.2%


The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Skin Cancer market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

F. Hoffmann-la Roche Ltd. (Switzerland), Novartis International AG (Switzerland), Sun Pharma Industries Ltd. (India), Elekta AB (Sweden), Varian Medical Systems Inc. (United States), Cannabis Science Inc. (United States), Cellceutix Corp. (United States), LEO Pharma A/S (Denmark), Moberg Pharma AB (Sweden), Mylan Pharmaceutical Inc. (United States), Oncothyreon Inc. (United States), Eli Lilly and Co. (United States), Bristol Myers Squibb Co. (United States), Boehringer Ingelheim GmbH (Germany), Aqua Pharmaceuticals LLC (United States) and Valeant Pharmaceuticals Inc. (Canada) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Meda AB (United States), iCAD Inc. (Sweden) and Merck & Co. Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Skin Cancer market by Type (Basal Cell Carcinoma, Squamous Cell Carcinoma and Malignant Melanoma), Application (Hospital, Clinics, Diagnostic Centers and Cancer Research Institute) and Region.



On the basis of geography, the market of Skin Cancer has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Chemotherapy Type, the sub-segment i.e. Systemic will boost the Skin Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Non- Invasive Treatment Type, the sub-segment i.e. Radiotherapy will boost the Skin Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment Type, the sub-segment i.e. Surgery will boost the Skin Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increased Focus by Companies in Developing Low-Cost Drugs, Use of Combination Therapies for the Procedure, Favorable Insurance and Reimbursement Policies and Increasing Strategic Alliances between the Companies

Market Growth Drivers:
Rising Shift towards Adoption of Western Lifestyle, Growing Incidents of Skin Cancers, Rise in Global Warming Leading to Depletion of Ozone Layer and Increasing Awareness about the Treatment Especially In the Emerging Nations

Challenges:
Severe Adverse Effects Associated With the Therapy

Restraints:
High Cost of Skin Cancer Therapeutics and Available Of Alternate Treatment Options

Opportunities:
Advancements in Cancer Biology, High Investment in R & D, Growing Technological Innovations for the Development of Drugs and Treatment and Launch of Several Diagnostic and Screening Programs Worldwide

Market Leaders and their expansionary development strategies
In June 2019, Pfizer Inc. and Array BioPharma Inc., announced that they have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need. Pfizer has agreed to acquire Array for 48 per share in cash, for a total enterprise value of approximately USD 11.4 billion. The Boards of Directors of both companies have approved the merger.
In January 2024, After two decades of providing comprehensive and accurate resources to the melanoma community, AIM at Melanoma has launched a new website called AIM at Skin Cancer. This new website will provide the same depth and breadth of resources and information to those battling nonmelanoma skin cancer.
Government initiatives to raise awareness of non-melanoma skin cancer

Key Target Audience
Providers of Cervical Cancer, End-Users, Potential Investors, Market Research Firms, Regulatory Bodies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Basal Cell Carcinoma
  • Squamous Cell Carcinoma
  • Malignant Melanoma
By Application
  • Hospital
  • Clinics
  • Diagnostic Centers
  • Cancer Research Institute
By Chemotherapy Type
  • Systemic
  • Targeted

By Non- Invasive Treatment Type
  • Radiotherapy
  • Photodynamic Therapy
  • Cryotherapy
  • Laser Therapy

By Treatment Type
  • Surgery
  • Medication

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Shift towards Adoption of Western Lifestyle
      • 3.2.2. Growing Incidents of Skin Cancers
      • 3.2.3. Rise in Global Warming Leading to Depletion of Ozone Layer
      • 3.2.4. Increasing Awareness about the Treatment Especially In the Emerging Nations
    • 3.3. Market Challenges
      • 3.3.1. Severe Adverse Effects Associated With the Therapy
    • 3.4. Market Trends
      • 3.4.1. Increased Focus by Companies in Developing Low-Cost Drugs
      • 3.4.2. Use of Combination Therapies for the Procedure
      • 3.4.3. Favorable Insurance and Reimbursement Policies
      • 3.4.4. Increasing Strategic Alliances between the Companies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Skin Cancer, by Type, Application, Chemotherapy Type, Non- Invasive Treatment Type, Treatment Type and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Skin Cancer (Value)
      • 5.2.1. Global Skin Cancer by: Type (Value)
        • 5.2.1.1. Basal Cell Carcinoma
        • 5.2.1.2. Squamous Cell Carcinoma
        • 5.2.1.3. Malignant Melanoma
      • 5.2.2. Global Skin Cancer by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinics
        • 5.2.2.3. Diagnostic Centers
        • 5.2.2.4. Cancer Research Institute
      • 5.2.3. Global Skin Cancer by: Chemotherapy Type (Value)
        • 5.2.3.1. Systemic
        • 5.2.3.2. Targeted
      • 5.2.4. Global Skin Cancer by: Non- Invasive Treatment Type (Value)
        • 5.2.4.1. Radiotherapy
        • 5.2.4.2. Photodynamic Therapy
        • 5.2.4.3. Cryotherapy
        • 5.2.4.4. Laser Therapy
      • 5.2.5. Global Skin Cancer by: Treatment Type (Value)
        • 5.2.5.1. Surgery
        • 5.2.5.2. Medication
      • 5.2.6. Global Skin Cancer Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Skin Cancer (Price)
      • 5.3.1. Global Skin Cancer by: Type (Price)
  • 6. Skin Cancer: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. F. Hoffmann-la Roche Ltd. (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis International AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sun Pharma Industries Ltd. (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Elekta AB (Sweden)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Varian Medical Systems Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Cannabis Science Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cellceutix Corp. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. LEO Pharma A/S (Denmark)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Moberg Pharma AB (Sweden)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mylan Pharmaceutical Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Oncothyreon Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Eli Lilly and Co. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Bristol Myers Squibb Co. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Boehringer Ingelheim GmbH (Germany)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Aqua Pharmaceuticals LLC (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Valeant Pharmaceuticals Inc. (Canada)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
  • 7. Global Skin Cancer Sale, by Type, Application, Chemotherapy Type, Non- Invasive Treatment Type, Treatment Type and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Skin Cancer (Value)
      • 7.2.1. Global Skin Cancer by: Type (Value)
        • 7.2.1.1. Basal Cell Carcinoma
        • 7.2.1.2. Squamous Cell Carcinoma
        • 7.2.1.3. Malignant Melanoma
      • 7.2.2. Global Skin Cancer by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinics
        • 7.2.2.3. Diagnostic Centers
        • 7.2.2.4. Cancer Research Institute
      • 7.2.3. Global Skin Cancer by: Chemotherapy Type (Value)
        • 7.2.3.1. Systemic
        • 7.2.3.2. Targeted
      • 7.2.4. Global Skin Cancer by: Non- Invasive Treatment Type (Value)
        • 7.2.4.1. Radiotherapy
        • 7.2.4.2. Photodynamic Therapy
        • 7.2.4.3. Cryotherapy
        • 7.2.4.4. Laser Therapy
      • 7.2.5. Global Skin Cancer by: Treatment Type (Value)
        • 7.2.5.1. Surgery
        • 7.2.5.2. Medication
      • 7.2.6. Global Skin Cancer Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Skin Cancer (Price)
      • 7.3.1. Global Skin Cancer by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Skin Cancer: by Type(USD Million)
  • Table 2. Skin Cancer Basal Cell Carcinoma , by Region USD Million (2018-2023)
  • Table 3. Skin Cancer Squamous Cell Carcinoma , by Region USD Million (2018-2023)
  • Table 4. Skin Cancer Malignant Melanoma , by Region USD Million (2018-2023)
  • Table 5. Skin Cancer: by Application(USD Million)
  • Table 6. Skin Cancer Hospital , by Region USD Million (2018-2023)
  • Table 7. Skin Cancer Clinics , by Region USD Million (2018-2023)
  • Table 8. Skin Cancer Diagnostic Centers , by Region USD Million (2018-2023)
  • Table 9. Skin Cancer Cancer Research Institute , by Region USD Million (2018-2023)
  • Table 10. Skin Cancer: by Chemotherapy Type(USD Million)
  • Table 11. Skin Cancer Systemic , by Region USD Million (2018-2023)
  • Table 12. Skin Cancer Targeted , by Region USD Million (2018-2023)
  • Table 13. Skin Cancer: by Non- Invasive Treatment Type(USD Million)
  • Table 14. Skin Cancer Radiotherapy , by Region USD Million (2018-2023)
  • Table 15. Skin Cancer Photodynamic Therapy , by Region USD Million (2018-2023)
  • Table 16. Skin Cancer Cryotherapy , by Region USD Million (2018-2023)
  • Table 17. Skin Cancer Laser Therapy , by Region USD Million (2018-2023)
  • Table 18. Skin Cancer: by Treatment Type(USD Million)
  • Table 19. Skin Cancer Surgery , by Region USD Million (2018-2023)
  • Table 20. Skin Cancer Medication , by Region USD Million (2018-2023)
  • Table 21. South America Skin Cancer, by Country USD Million (2018-2023)
  • Table 22. South America Skin Cancer, by Type USD Million (2018-2023)
  • Table 23. South America Skin Cancer, by Application USD Million (2018-2023)
  • Table 24. South America Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 25. South America Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 26. South America Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 27. Brazil Skin Cancer, by Type USD Million (2018-2023)
  • Table 28. Brazil Skin Cancer, by Application USD Million (2018-2023)
  • Table 29. Brazil Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 30. Brazil Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 31. Brazil Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 32. Argentina Skin Cancer, by Type USD Million (2018-2023)
  • Table 33. Argentina Skin Cancer, by Application USD Million (2018-2023)
  • Table 34. Argentina Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 35. Argentina Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 36. Argentina Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 37. Rest of South America Skin Cancer, by Type USD Million (2018-2023)
  • Table 38. Rest of South America Skin Cancer, by Application USD Million (2018-2023)
  • Table 39. Rest of South America Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 40. Rest of South America Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 41. Rest of South America Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 42. Asia Pacific Skin Cancer, by Country USD Million (2018-2023)
  • Table 43. Asia Pacific Skin Cancer, by Type USD Million (2018-2023)
  • Table 44. Asia Pacific Skin Cancer, by Application USD Million (2018-2023)
  • Table 45. Asia Pacific Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 46. Asia Pacific Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 47. Asia Pacific Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 48. China Skin Cancer, by Type USD Million (2018-2023)
  • Table 49. China Skin Cancer, by Application USD Million (2018-2023)
  • Table 50. China Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 51. China Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 52. China Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 53. Japan Skin Cancer, by Type USD Million (2018-2023)
  • Table 54. Japan Skin Cancer, by Application USD Million (2018-2023)
  • Table 55. Japan Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 56. Japan Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 57. Japan Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 58. India Skin Cancer, by Type USD Million (2018-2023)
  • Table 59. India Skin Cancer, by Application USD Million (2018-2023)
  • Table 60. India Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 61. India Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 62. India Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 63. South Korea Skin Cancer, by Type USD Million (2018-2023)
  • Table 64. South Korea Skin Cancer, by Application USD Million (2018-2023)
  • Table 65. South Korea Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 66. South Korea Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 67. South Korea Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 68. Taiwan Skin Cancer, by Type USD Million (2018-2023)
  • Table 69. Taiwan Skin Cancer, by Application USD Million (2018-2023)
  • Table 70. Taiwan Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 71. Taiwan Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 72. Taiwan Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 73. Australia Skin Cancer, by Type USD Million (2018-2023)
  • Table 74. Australia Skin Cancer, by Application USD Million (2018-2023)
  • Table 75. Australia Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 76. Australia Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 77. Australia Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 78. Rest of Asia-Pacific Skin Cancer, by Type USD Million (2018-2023)
  • Table 79. Rest of Asia-Pacific Skin Cancer, by Application USD Million (2018-2023)
  • Table 80. Rest of Asia-Pacific Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 81. Rest of Asia-Pacific Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 82. Rest of Asia-Pacific Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 83. Europe Skin Cancer, by Country USD Million (2018-2023)
  • Table 84. Europe Skin Cancer, by Type USD Million (2018-2023)
  • Table 85. Europe Skin Cancer, by Application USD Million (2018-2023)
  • Table 86. Europe Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 87. Europe Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 88. Europe Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 89. Germany Skin Cancer, by Type USD Million (2018-2023)
  • Table 90. Germany Skin Cancer, by Application USD Million (2018-2023)
  • Table 91. Germany Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 92. Germany Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 93. Germany Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 94. France Skin Cancer, by Type USD Million (2018-2023)
  • Table 95. France Skin Cancer, by Application USD Million (2018-2023)
  • Table 96. France Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 97. France Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 98. France Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 99. Italy Skin Cancer, by Type USD Million (2018-2023)
  • Table 100. Italy Skin Cancer, by Application USD Million (2018-2023)
  • Table 101. Italy Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 102. Italy Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 103. Italy Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 104. United Kingdom Skin Cancer, by Type USD Million (2018-2023)
  • Table 105. United Kingdom Skin Cancer, by Application USD Million (2018-2023)
  • Table 106. United Kingdom Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 107. United Kingdom Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 108. United Kingdom Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 109. Netherlands Skin Cancer, by Type USD Million (2018-2023)
  • Table 110. Netherlands Skin Cancer, by Application USD Million (2018-2023)
  • Table 111. Netherlands Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 112. Netherlands Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 113. Netherlands Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 114. Rest of Europe Skin Cancer, by Type USD Million (2018-2023)
  • Table 115. Rest of Europe Skin Cancer, by Application USD Million (2018-2023)
  • Table 116. Rest of Europe Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 117. Rest of Europe Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 118. Rest of Europe Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 119. MEA Skin Cancer, by Country USD Million (2018-2023)
  • Table 120. MEA Skin Cancer, by Type USD Million (2018-2023)
  • Table 121. MEA Skin Cancer, by Application USD Million (2018-2023)
  • Table 122. MEA Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 123. MEA Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 124. MEA Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 125. Middle East Skin Cancer, by Type USD Million (2018-2023)
  • Table 126. Middle East Skin Cancer, by Application USD Million (2018-2023)
  • Table 127. Middle East Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 128. Middle East Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 129. Middle East Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 130. Africa Skin Cancer, by Type USD Million (2018-2023)
  • Table 131. Africa Skin Cancer, by Application USD Million (2018-2023)
  • Table 132. Africa Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 133. Africa Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 134. Africa Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 135. North America Skin Cancer, by Country USD Million (2018-2023)
  • Table 136. North America Skin Cancer, by Type USD Million (2018-2023)
  • Table 137. North America Skin Cancer, by Application USD Million (2018-2023)
  • Table 138. North America Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 139. North America Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 140. North America Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 141. United States Skin Cancer, by Type USD Million (2018-2023)
  • Table 142. United States Skin Cancer, by Application USD Million (2018-2023)
  • Table 143. United States Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 144. United States Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 145. United States Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 146. Canada Skin Cancer, by Type USD Million (2018-2023)
  • Table 147. Canada Skin Cancer, by Application USD Million (2018-2023)
  • Table 148. Canada Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 149. Canada Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 150. Canada Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 151. Mexico Skin Cancer, by Type USD Million (2018-2023)
  • Table 152. Mexico Skin Cancer, by Application USD Million (2018-2023)
  • Table 153. Mexico Skin Cancer, by Chemotherapy Type USD Million (2018-2023)
  • Table 154. Mexico Skin Cancer, by Non- Invasive Treatment Type USD Million (2018-2023)
  • Table 155. Mexico Skin Cancer, by Treatment Type USD Million (2018-2023)
  • Table 156. Skin Cancer: by Type(USD/Units)
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Skin Cancer: by Type(USD Million)
  • Table 174. Skin Cancer Basal Cell Carcinoma , by Region USD Million (2025-2030)
  • Table 175. Skin Cancer Squamous Cell Carcinoma , by Region USD Million (2025-2030)
  • Table 176. Skin Cancer Malignant Melanoma , by Region USD Million (2025-2030)
  • Table 177. Skin Cancer: by Application(USD Million)
  • Table 178. Skin Cancer Hospital , by Region USD Million (2025-2030)
  • Table 179. Skin Cancer Clinics , by Region USD Million (2025-2030)
  • Table 180. Skin Cancer Diagnostic Centers , by Region USD Million (2025-2030)
  • Table 181. Skin Cancer Cancer Research Institute , by Region USD Million (2025-2030)
  • Table 182. Skin Cancer: by Chemotherapy Type(USD Million)
  • Table 183. Skin Cancer Systemic , by Region USD Million (2025-2030)
  • Table 184. Skin Cancer Targeted , by Region USD Million (2025-2030)
  • Table 185. Skin Cancer: by Non- Invasive Treatment Type(USD Million)
  • Table 186. Skin Cancer Radiotherapy , by Region USD Million (2025-2030)
  • Table 187. Skin Cancer Photodynamic Therapy , by Region USD Million (2025-2030)
  • Table 188. Skin Cancer Cryotherapy , by Region USD Million (2025-2030)
  • Table 189. Skin Cancer Laser Therapy , by Region USD Million (2025-2030)
  • Table 190. Skin Cancer: by Treatment Type(USD Million)
  • Table 191. Skin Cancer Surgery , by Region USD Million (2025-2030)
  • Table 192. Skin Cancer Medication , by Region USD Million (2025-2030)
  • Table 193. South America Skin Cancer, by Country USD Million (2025-2030)
  • Table 194. South America Skin Cancer, by Type USD Million (2025-2030)
  • Table 195. South America Skin Cancer, by Application USD Million (2025-2030)
  • Table 196. South America Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 197. South America Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 198. South America Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 199. Brazil Skin Cancer, by Type USD Million (2025-2030)
  • Table 200. Brazil Skin Cancer, by Application USD Million (2025-2030)
  • Table 201. Brazil Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 202. Brazil Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 203. Brazil Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 204. Argentina Skin Cancer, by Type USD Million (2025-2030)
  • Table 205. Argentina Skin Cancer, by Application USD Million (2025-2030)
  • Table 206. Argentina Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 207. Argentina Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 208. Argentina Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 209. Rest of South America Skin Cancer, by Type USD Million (2025-2030)
  • Table 210. Rest of South America Skin Cancer, by Application USD Million (2025-2030)
  • Table 211. Rest of South America Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 212. Rest of South America Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 213. Rest of South America Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 214. Asia Pacific Skin Cancer, by Country USD Million (2025-2030)
  • Table 215. Asia Pacific Skin Cancer, by Type USD Million (2025-2030)
  • Table 216. Asia Pacific Skin Cancer, by Application USD Million (2025-2030)
  • Table 217. Asia Pacific Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 218. Asia Pacific Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 219. Asia Pacific Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 220. China Skin Cancer, by Type USD Million (2025-2030)
  • Table 221. China Skin Cancer, by Application USD Million (2025-2030)
  • Table 222. China Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 223. China Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 224. China Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 225. Japan Skin Cancer, by Type USD Million (2025-2030)
  • Table 226. Japan Skin Cancer, by Application USD Million (2025-2030)
  • Table 227. Japan Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 228. Japan Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 229. Japan Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 230. India Skin Cancer, by Type USD Million (2025-2030)
  • Table 231. India Skin Cancer, by Application USD Million (2025-2030)
  • Table 232. India Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 233. India Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 234. India Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 235. South Korea Skin Cancer, by Type USD Million (2025-2030)
  • Table 236. South Korea Skin Cancer, by Application USD Million (2025-2030)
  • Table 237. South Korea Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 238. South Korea Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 239. South Korea Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 240. Taiwan Skin Cancer, by Type USD Million (2025-2030)
  • Table 241. Taiwan Skin Cancer, by Application USD Million (2025-2030)
  • Table 242. Taiwan Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 243. Taiwan Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 244. Taiwan Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 245. Australia Skin Cancer, by Type USD Million (2025-2030)
  • Table 246. Australia Skin Cancer, by Application USD Million (2025-2030)
  • Table 247. Australia Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 248. Australia Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 249. Australia Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 250. Rest of Asia-Pacific Skin Cancer, by Type USD Million (2025-2030)
  • Table 251. Rest of Asia-Pacific Skin Cancer, by Application USD Million (2025-2030)
  • Table 252. Rest of Asia-Pacific Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 253. Rest of Asia-Pacific Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 254. Rest of Asia-Pacific Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 255. Europe Skin Cancer, by Country USD Million (2025-2030)
  • Table 256. Europe Skin Cancer, by Type USD Million (2025-2030)
  • Table 257. Europe Skin Cancer, by Application USD Million (2025-2030)
  • Table 258. Europe Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 259. Europe Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 260. Europe Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 261. Germany Skin Cancer, by Type USD Million (2025-2030)
  • Table 262. Germany Skin Cancer, by Application USD Million (2025-2030)
  • Table 263. Germany Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 264. Germany Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 265. Germany Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 266. France Skin Cancer, by Type USD Million (2025-2030)
  • Table 267. France Skin Cancer, by Application USD Million (2025-2030)
  • Table 268. France Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 269. France Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 270. France Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 271. Italy Skin Cancer, by Type USD Million (2025-2030)
  • Table 272. Italy Skin Cancer, by Application USD Million (2025-2030)
  • Table 273. Italy Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 274. Italy Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 275. Italy Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 276. United Kingdom Skin Cancer, by Type USD Million (2025-2030)
  • Table 277. United Kingdom Skin Cancer, by Application USD Million (2025-2030)
  • Table 278. United Kingdom Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 279. United Kingdom Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 280. United Kingdom Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 281. Netherlands Skin Cancer, by Type USD Million (2025-2030)
  • Table 282. Netherlands Skin Cancer, by Application USD Million (2025-2030)
  • Table 283. Netherlands Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 284. Netherlands Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 285. Netherlands Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 286. Rest of Europe Skin Cancer, by Type USD Million (2025-2030)
  • Table 287. Rest of Europe Skin Cancer, by Application USD Million (2025-2030)
  • Table 288. Rest of Europe Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 289. Rest of Europe Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 290. Rest of Europe Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 291. MEA Skin Cancer, by Country USD Million (2025-2030)
  • Table 292. MEA Skin Cancer, by Type USD Million (2025-2030)
  • Table 293. MEA Skin Cancer, by Application USD Million (2025-2030)
  • Table 294. MEA Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 295. MEA Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 296. MEA Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 297. Middle East Skin Cancer, by Type USD Million (2025-2030)
  • Table 298. Middle East Skin Cancer, by Application USD Million (2025-2030)
  • Table 299. Middle East Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 300. Middle East Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 301. Middle East Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 302. Africa Skin Cancer, by Type USD Million (2025-2030)
  • Table 303. Africa Skin Cancer, by Application USD Million (2025-2030)
  • Table 304. Africa Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 305. Africa Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 306. Africa Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 307. North America Skin Cancer, by Country USD Million (2025-2030)
  • Table 308. North America Skin Cancer, by Type USD Million (2025-2030)
  • Table 309. North America Skin Cancer, by Application USD Million (2025-2030)
  • Table 310. North America Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 311. North America Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 312. North America Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 313. United States Skin Cancer, by Type USD Million (2025-2030)
  • Table 314. United States Skin Cancer, by Application USD Million (2025-2030)
  • Table 315. United States Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 316. United States Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 317. United States Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 318. Canada Skin Cancer, by Type USD Million (2025-2030)
  • Table 319. Canada Skin Cancer, by Application USD Million (2025-2030)
  • Table 320. Canada Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 321. Canada Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 322. Canada Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 323. Mexico Skin Cancer, by Type USD Million (2025-2030)
  • Table 324. Mexico Skin Cancer, by Application USD Million (2025-2030)
  • Table 325. Mexico Skin Cancer, by Chemotherapy Type USD Million (2025-2030)
  • Table 326. Mexico Skin Cancer, by Non- Invasive Treatment Type USD Million (2025-2030)
  • Table 327. Mexico Skin Cancer, by Treatment Type USD Million (2025-2030)
  • Table 328. Skin Cancer: by Type(USD/Units)
  • Table 329. Research Programs/Design for This Report
  • Table 330. Key Data Information from Secondary Sources
  • Table 331. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Skin Cancer: by Type USD Million (2018-2023)
  • Figure 5. Global Skin Cancer: by Application USD Million (2018-2023)
  • Figure 6. Global Skin Cancer: by Chemotherapy Type USD Million (2018-2023)
  • Figure 7. Global Skin Cancer: by Non- Invasive Treatment Type USD Million (2018-2023)
  • Figure 8. Global Skin Cancer: by Treatment Type USD Million (2018-2023)
  • Figure 9. South America Skin Cancer Share (%), by Country
  • Figure 10. Asia Pacific Skin Cancer Share (%), by Country
  • Figure 11. Europe Skin Cancer Share (%), by Country
  • Figure 12. MEA Skin Cancer Share (%), by Country
  • Figure 13. North America Skin Cancer Share (%), by Country
  • Figure 14. Global Skin Cancer: by Type USD/Units (2018-2023)
  • Figure 15. Global Skin Cancer share by Players 2023 (%)
  • Figure 16. Global Skin Cancer share by Players (Top 3) 2023(%)
  • Figure 17. Global Skin Cancer share by Players (Top 5) 2023(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. F. Hoffmann-la Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. F. Hoffmann-la Roche Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 21. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 23. Sun Pharma Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 24. Sun Pharma Industries Ltd. (India) Revenue: by Geography 2023
  • Figure 25. Elekta AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 26. Elekta AB (Sweden) Revenue: by Geography 2023
  • Figure 27. Varian Medical Systems Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Varian Medical Systems Inc. (United States) Revenue: by Geography 2023
  • Figure 29. Cannabis Science Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Cannabis Science Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Cellceutix Corp. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Cellceutix Corp. (United States) Revenue: by Geography 2023
  • Figure 33. LEO Pharma A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 34. LEO Pharma A/S (Denmark) Revenue: by Geography 2023
  • Figure 35. Moberg Pharma AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 36. Moberg Pharma AB (Sweden) Revenue: by Geography 2023
  • Figure 37. Mylan Pharmaceutical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Mylan Pharmaceutical Inc. (United States) Revenue: by Geography 2023
  • Figure 39. Oncothyreon Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Oncothyreon Inc. (United States) Revenue: by Geography 2023
  • Figure 41. Eli Lilly and Co. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Eli Lilly and Co. (United States) Revenue: by Geography 2023
  • Figure 43. Bristol Myers Squibb Co. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Bristol Myers Squibb Co. (United States) Revenue: by Geography 2023
  • Figure 45. Boehringer Ingelheim GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 46. Boehringer Ingelheim GmbH (Germany) Revenue: by Geography 2023
  • Figure 47. Aqua Pharmaceuticals LLC (United States) Revenue, Net Income and Gross profit
  • Figure 48. Aqua Pharmaceuticals LLC (United States) Revenue: by Geography 2023
  • Figure 49. Valeant Pharmaceuticals Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 50. Valeant Pharmaceuticals Inc. (Canada) Revenue: by Geography 2023
  • Figure 51. Global Skin Cancer: by Type USD Million (2025-2030)
  • Figure 52. Global Skin Cancer: by Application USD Million (2025-2030)
  • Figure 53. Global Skin Cancer: by Chemotherapy Type USD Million (2025-2030)
  • Figure 54. Global Skin Cancer: by Non- Invasive Treatment Type USD Million (2025-2030)
  • Figure 55. Global Skin Cancer: by Treatment Type USD Million (2025-2030)
  • Figure 56. South America Skin Cancer Share (%), by Country
  • Figure 57. Asia Pacific Skin Cancer Share (%), by Country
  • Figure 58. Europe Skin Cancer Share (%), by Country
  • Figure 59. MEA Skin Cancer Share (%), by Country
  • Figure 60. North America Skin Cancer Share (%), by Country
  • Figure 61. Global Skin Cancer: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • F. Hoffmann-la Roche Ltd. (Switzerland)
  • Novartis International AG (Switzerland)
  • Sun Pharma Industries Ltd. (India)
  • Elekta AB (Sweden)
  • Varian Medical Systems Inc. (United States)
  • Cannabis Science Inc. (United States)
  • Cellceutix Corp. (United States)
  • LEO Pharma A/S (Denmark)
  • Moberg Pharma AB (Sweden)
  • Mylan Pharmaceutical Inc. (United States)
  • Oncothyreon Inc. (United States)
  • Eli Lilly and Co. (United States)
  • Bristol Myers Squibb Co. (United States)
  • Boehringer Ingelheim GmbH (Germany)
  • Aqua Pharmaceuticals LLC (United States)
  • Valeant Pharmaceuticals Inc. (Canada)
Additional players considered in the study are as follows:
Meda AB (United States) , iCAD Inc. (Sweden) , Merck & Co. Inc. (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 176 Pages 52 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Skin Cancer Quantitative research analysis
Global Skin Cancer Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as F. Hoffmann-la Roche Ltd. (Switzerland), Novartis International AG (Switzerland), Sun Pharma Industries Ltd. (India), Elekta AB (Sweden), Varian Medical Systems Inc. (United States), Cannabis Science Inc. (United States), Cellceutix Corp. (United States), LEO Pharma A/S (Denmark), Moberg Pharma AB (Sweden), Mylan Pharmaceutical Inc. (United States), Oncothyreon Inc. (United States), Eli Lilly and Co. (United States), Bristol Myers Squibb Co. (United States), Boehringer Ingelheim GmbH (Germany), Aqua Pharmaceuticals LLC (United States) and Valeant Pharmaceuticals Inc. (Canada) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increased Focus by Companies in Developing Low-Cost Drugs " is seen as one of major influencing trends for Skin Cancer Market during projected period 2023-2030.
The Skin Cancer market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Skin Cancer Report?

Have a Query? Click Here

Other Related Reports

Health Product Comprehensive Study by Type (Food tolerance, Fortified food products, Others), Application (Hospital, Pharmacy, Clinics, Household, Others), Distribution channel (Supermarket, Hypermar...
$ 3750
TMJ Implants Comprehensive Study by Type (Mandibular Components, Fossa Prostheses, Screws components), Application (Arthritic Conditions, Ankylosis, Others), End-User (Hospitals, OPDs, Dental Clinics...
$ 3800
Critical Condition Surveillance Systems Comprehensive Study by Application (Hospital, Ambulatory Surgical, Diagnostic Centers, Clinic), Component (Hardware, Software), Deployment (On Premise, Cloud)...
$ 3400
Clary Sage Comprehensive Study by Type (Oil, Powder), Application (Healthcare Products, Personal Care Products, Food and Beverage, Others), Sales Channel (Direct Sales, Indirect Sales {Speciality Sto...
$ 3450
Pet Utility Products Comprehensive Study by Type (Pet Collars, Leashes, Feeding Accessories, Other), Sales Channel (Online Stores, Veterinary Hospitals & Clinics, Pet Shops, Other), Animal (Dogs, Ca...
$ 3450
Fitness and Recreational Sports Centers Comprehensive Study by Type (Gymnasiums, Yoga, Aerobic dance, Handball sports, Racquet sports, Skating, Swimming, Others), Application (35 & Younger, 35-54, 55...
$ 3350